SCHEMBL264454

SCHEMBL264454

C[C@H]1C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14230823 1.00
SCHEMBL6142704 1.00
SCHEMBL10201228 1.00
SCHEMBL14198626 1.00
SCHEMBL12928828 1.00
SCHEMBL12899682 1.00
SCHEMBL12899649 1.00
SCHEMBL12222437 1.00
SCHEMBL5021289 1.00
SCHEMBL12149455 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
EP-1167972-B1 Enzyme catalyzed therapeutic agents KIADIS PHARMA INTELLECTUAL PROPERTY B V (NL) 2017-03-08 EP disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 EP disclosed
EP-2699240-B1 ACADESINE DERIVATIVES, PRODUCTS AND COMPOSITIONS INCLUDING SAME, THERAPEUTIC USES THEREOF, AND METHODS FOR SYNTHESIZING SAME UNIVERSITÉ NICE SOPHIA ANTIPOLIS (FR) 2015-05-27 EP disclosed
US-8883758-B2 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof ANADYS PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
US-20130259831-A1 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof ANADYS PHARMACEUTICALS, INC. (US) 2013-10-03 US disclosed
US-8440813-B2 Antiviral nucleoside analogs BIOCRYST PHARMACEUTICALS, INC. (US) 2013-05-14 US disclosed
US-8440813-B2 Antiviral nucleoside analogs BIOCRYST PHARMACEUTICALS, INC. (US) 2013-05-14 US disclosed
US-8377717-B2 Site selectively tagged and templated molecularly imprinted polymers for sensor applications THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2013-02-19 US disclosed
US-8334364-B2 High-molecular weight derivative of nucleic acid antimetabolite NIPON KAYAKU KABUSHIKI KAISHA (JP) 2012-12-18 US disclosed
US-20100015094-A1 ANTIVIRAL NUCLEOSIDE ANALOGS WILMINGTON TRUST, NATIONAL ASSOCIATION 2010-01-21 US disclosed
US-20090281300-A1 HIGH-MOLECULAR WEIGHT DERIVATIVE OF NUCLEIC ACID ANTIMETABOLITE NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-11-12 US disclosed
US-7605144-B2 Enzyme catalyzed therapeutic compounds CELMED ONCOLOGY (USA), INC. (CA) 2009-10-20 US disclosed
US-20090227524-A1 ANTIVIRAL THERAPEUTIC AGENTS BIOCRYST PHARMACEUTICALS, INC. (US) 2009-09-10 US disclosed
EP-2080779-A1 POLYMERIC DERIVATIVE OF NUCLEIC ACID METABOLIC ANTAGONIST Nippon Kayaku Kabushiki Kaisha (JP) 2009-07-22 EP disclosed
US-7514410-B2 Hepatitis C therapies BIOCRYST PHARMACEUTICALS, INC. (US) 2009-04-07 US disclosed
US-7514410-B2 Hepatitis C therapies BIOCRYST PHARMACEUTICALS, INC. (US) 2009-04-07 US disclosed
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-12-04 US disclosed
US-7429571-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed
US-7419968-B1 Methods for treating therapy-resistant tumors CELMED ONCOLOGY (USA), INC. (CA) 2008-09-02 US disclosed